套细胞淋巴瘤CAR-T细胞治疗后疾病进展的治疗模式与结局:一项多中心分析
该多中心分析纳入15个国际中心接受CD19 CAR-T细胞治疗的384例复发或难治性套细胞淋巴瘤患者,其中135例(35%)出现疾病进展,进展后中位无进展生存期2.5个月、中位总生存期5.4个月,对CAR-T无反应及输注至进展时间短与进展后总生存期较差相关。
要点
- 384例接受CD19 CAR-T细胞治疗的患者中135例(35%)出现疾病进展,进展中位时间为输注后6个月。
- 进展后最常用一线系统治疗方案为化学免疫治疗(22例,ORR 40%)、pirtobrutinib(17例,ORR 36%)和双特异性抗体(13例,ORR 67%)。
- 进展后中位无进展生存期2.5个月、中位总生存期5.4个月,对CAR-T无反应及输注至进展时间短与总生存期较差相关。
核心结论
- 研究证实复发或难治性套细胞淋巴瘤患者在接受CD19 CAR-T细胞治疗后出现疾病进展者预后具有挑战性,并为该人群的未来研究建立了基准。
研究设计与样本
- 研究纳入15个国际中心接受CD19 CAR-T细胞治疗的全部复发或难治性套细胞淋巴瘤患者,并详细分析其中出现疾病进展者,提取临床、治疗和病理变量并与生存结局关联。
主要发现
- 384例患者接受CAR-T细胞治疗,135例(35%)出现疾病进展,进展中位时间为CAR-T细胞输注后6个月,多数(64%)进展患者的最佳疗效为完全缓解。
- 进展时肿瘤特征包括78例中29例(37%)呈母细胞样或多形性形态,41例中21例(51%)存在TP53突变。
- 进展后17例未接受进一步治疗,13例接受局部治疗,105例接受系统治疗。
- 进展后最常用一线系统治疗为化学免疫治疗(22例,总缓解率40%)、pirtobrutinib(17例,总缓解率36%)和双特异性抗体(13例,总缓解率67%)。
- 进展患者自进展起中位无进展生存期2.5个月、中位总生存期5.4个月,对CAR-T细胞治疗无反应及输注至进展时间短(<3个月 vs 3-6个月 vs >6个月)等因素与进展后总生存期较差相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post-CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to CAR T-cell therapy. Tumor features at POD included blastoid/pleomorphic morphology in 29 of 78 (37%) patients, and TP53 mutation in 21 of 41 (51%) patients. Following POD, 17 patients received no further therapy, 13 underwent local therapy, and 105 received systemic therapy. The most common first-line systemic therapies were chemo(immuno)therapy (22 patients; overall response rate [ORR], 40%), pirtobrutinib (17 patients; ORR, 36%), and bispecific antibodies (13 patients; ORR, 67%). Among patients experiencing POD, the median progression-free survival and overall survival (OS) were 2.5 months and 5.4 months, respectively, from POD. Lack of response to CAR T-cell therapy and short time from CAR T-cell therapy infusion to POD (<3 vs 3-6 vs >6 months), among other factors, were associated with inferior OS after POD. In conclusion, we confirm the challenging prognosis for patients experiencing POD following CD19 CAR T-cell therapy for R/R MCL, and establish a benchmark for future investigations in this patient population.
引用
- Epstein-Peterson ZD, Lionel AC, Joseph A, et al. Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. Blood Adv. 2025. PMID: 40763269. doi:10.1182/bloodadvances.2025016315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。